SynthesisBMJ clinical evidence2008
Cellulitis and erysipelas.
Synthesis in BMJ clinical evidence, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review showing the lack of diagnostic criteria and tools developed for lower-limb cellulitis.The British journal of dermatology · 2019Pooled it
- Interventions for the prevention of recurrent erysipelas and cellulitis.The Cochrane database of systematic reviews · 2017Pooled it
- Comparing short to standard duration of antibiotic therapy for patients hospitalized with cellulitis (DANCE): study protocol for a randomized controlled trial.BMC infectious diseases · 2014Trial
- Progress in topical nanoformulations against bacterial skin and soft tissue infections- current trends.Drug delivery and translational research · 2025Review
- A rare case of necrotic erysipelas of the breast in a healthy, postpartum female.Journal of surgical case reports · 2025Article
- Article
- Practice and community nurses' views and experiences of helping people manage risk factors for recurrent lower limb cellulitis: A qualitative interview study.Skin health and disease · 2024Article
- Group A Streptococcal Infections in Pediatric Age: Updates about a Re-Emerging Pathogen.Pathogens (Basel, Switzerland) · 2024Review
- Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management.American journal of clinical dermatology · 2023Review
- Kawasaki Disease with an Initial Manifestation Mimicking Bacterial Inguinal Cellulitis.Case reports in pediatrics · 2020Article
- Lessons Learned From a Randomized Controlled Trial of Short-Course Intravenous Antibiotic Therapy for Erysipelas and Cellulitis of the Lower Limb (Switch Trial).Open forum infectious diseases · 2019Article
- Evaluation of Antibiotic Treatment on the Duration of Hospitalization of Patients with Erysipelas and Bacterial Cellulitis.Dermatology and therapy · 2019Article
- 2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections.World journal of emergency surgery : WJES · 2018Review
- Seasonality of cellulitis: evidence from Google Trends.Infection and drug resistance · 2018Article
- Orofacial Bacterial Infectious Diseases: An Update.Journal of International Society of Preventive & Community Dentistry · 2017Review
- World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections.World journal of emergency surgery : WJES · 2014Review
- Variability of antimicrobial prescribing in patients with acute cellulitis.European journal of clinical pharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCellulitis is a common problem, caused by spreading bacterial inflammation of the skin, with redness, pain, and lymphangitis. Up to 40% of affected people have systemic illness. Erysipelas is a form of cellulitis with marked superficial inflammation, typically affecting the lower limbs and the face. The most common pathogens in adults are streptococci and Staphylococcus aureus. Cellulitis and erysipelas can result in local necrosis and abscess formation. Around a quarter of affected people have more than one episode of cellulitis within 3 years. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for cellulitis and erysipelas? What are the effects of treatments to prevent recurrence of cellulitis and erysipelas? We searched: Medline, Embase, The Cochrane Library and other important databases up to May 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
resultsWe found 14 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
conclusionsIn this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics, comparative effects of different antibiotic regimens, duration of antibiotics, and treatment of predisposing factors.
Indexed as
Identifiers
19450336PMC2907977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.